The MAb-based drug market is one of the fastest growing categories of the biopharmaceuticals industry. These products are of high value for pharmaceutical industry, both in research as well as drug development activities.

Biosimilar biologics are complex protein structures. The highly experienced BioXpress Therapeutics team has worked on the development of 12 originator MAbs currently on the market. Since Q2 2010, BioXpress Therapeutics has completed the validation of protein sequence, cell line development, analysis of production cell line, and pre-Phase I clinical plans for its first four biosimilar MAbs: adalimumab, bevacizumab, rituximab and trastuzumab.

Each BioXpress Therapeutics monoclonal antibody (MAb) biosimilar drug is developed under strict non-clinical and clinical guidelines as outlined in the European Medicines Agency’s “Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies.” Furthermore, each BioXpress Therapeutics biosimilar goes through a complete analytical comparison to determine the product is similar to the innovator product.

To ensure BioXpress Therapeutics has identified the best opportunity within the MAb biosimilar arena, the Company has developed a proprietary database of twenty-five data points for each drug, based on comprehensive analysis of literature and patent databases. All data entry and data analysis is done by the Company’s team, which consists of scientists who have been actively involved in making monoclonal antibody therapeutics since the early 1980s. As a result, the BioXpress scientific team is well versed in the literature and groups who have developed many of the originator MAbs over the decades.




Viroblock SA is a start up focused on developing and out-licensing anti-viral products.  Our core technology uses catalytic vesicles to inactivate a broad spectrum of enveloped viruses such as human and avian influenzas, SARS, HIV, Ebola, Marburg and Smallpox viruses.  In-vitro and in-vivo testing on model systems has validated the technology and the company is now focused on developing a pre-impregnated anti-viral mask for launch in 2012. The venture is supported by CTI Start-up and FONGIT.

Viroblock’s catalytic vesicles can be formulated into gels, creams, and sprays or coated onto fabrics. The first commercial product will be an antiviral mask offering viral kill on pass through air. This product has use in a wide variety of Healthcare, Public Health, Homeland Security, Biodefense and Veterinary situations. Revenue streams will be generated via licenses and royalties.

The spectrum and fast acting anti-viral technology offers the possibility to make unique viral kill claims on pass through air (mask product). Flexible and robust technology offering multiple product executions – masks, air filtration products, anti-viral fabrics, nasal sprays, vaginal gels, and so forth.




Abionic has developed a novel technology for allergy diagnoses promoting personalized medication. The first product line, abioScope and abioDisc will greatly reduce the costs and time of the widely used blood tests, performed by third party contracted laboratories. The products are expected to be launched in late 2012.  Read more […]
The Aïmago EasyLDI is the only fast and non-invasive microcirculation camera that empowers surgeons and nurses to make better decisions, both during surgery and outside the OR. Our goal is to develop and commercialize an easy-to-use and innovative diagnostic imaging solutions to visualize microcirculation and related functional and metabolic parameters.  Read more […]
Anteis is one of the worldwide actors specialized in the development, manufacturing and distribution of innovative injectable medical devices based on biopolymer transformation. Our innovations portfolio includes diverse biopolymer-based injectable gels and injection systems for gel-based products.  We provide revolutionary solutions tailored to aesthetic dermatology, ophthalmology and orthopaedics.  Read more […]
BioXpress Therapeutics SA (BXT) is a premier provider of high-quality biosimilar monoclonal antibody (MAbs) for unmet need indications. BXT is focused on developing the highest quality product under strict European Medicines Agency (EMA) guidelines. We bring together the world’s top biologic development, manufacturing and regulatory experts dedicated to assuring the quality of our drugs.  Read more […]
CELLnTEC has developed a new generation of culture media specifically designed to target epithelial stem cells in tissues such as the skin, cornea, and airway. Cells growing in our media also retain the ability to form complex and dynamic 3D organ cultures in vitro, enabling more accurate modelling of complex mechanisms that surrogates animal tests. We are a spinoff from the University of Bern.  Read more […]
inZair revolutionizes mobile messaging with ZMS.  This application combines multimedia rich content, like text, pictures, video and audio, with geolocation and time scheduled message broadcasting.  inZair was awarded the AlpICT & Accenture Innovation Prize at LIFT’12 and is finalist at the next European Venture Summit 2012.  ZMS was launched last December and has users in about 60 countries.  Read more […]
TBS Insight, a medical software package, allows clinicians to quickly assess bone micro architectures and to significantly improve osteoporosis diagnosis, i.e. the management, in routine clinical practice.  The patented and proprietary TBS algorithm reanalyzes the changes in bone densitometry grayscale images (DXA) to compute bone fracture risks.  The technology has Dental and Orthopedics applications.  Read more […]
Its software suite is designed to specifically ease the strain on information workers by providing semantic search, automatic categorization and conceptually related content. This groundbreaking technology, combines Language Acquisition techniques and Latent Semantic Analysis (LSA) to form a conceptual and contextual understanding of any piece of textual information.  Read more […]
Selexis SA is a global life science company with technologies for drug discovery, high-performance mammalian cell line development and scale-up to manufacturing of therapeutic proteins (e.g. monoclonal antibodies, growth factors, enzymes). From discovery to Phase II clinical trials, our technology has been and is currently being used by more than 50 leading biotechnology and pharmaceutical companies worldwide.  Read more […]
Viroblock will launch a breakthrough anti-viral face mask by 2012.  It uses a patented coating to kill all such viruses on pass through air thereby protecting the wearer and reducing infection.  Our technology has been shown to kill all enveloped viruses tested, including H1N1, H5N1, SARS, and HIV. No resistance has been seen nor is expected as Viroblock technology targets a non-coded part of these viruses.  Read more […]